Reozalimab
Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research[1][2].
Product Specifications
CAS Number
[2445259-99-2]
Product Name Alternative
LY3434172
UNSPSC
12352203
Target
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/reozalimab.html
Purity
99.90
Solubility
10 mM in DMSO|H2O
Smiles
[Reozalimab]
Molecular Weight
(143.55 kDa)
References & Citations
[1]Pattabiraman, et al. Synthetic IL-7 and IL-7-anti-PD-1 antibody immunocytokines for cancer therapy. World Intellectual Property Organization, WO2023281484 A1 2023-01-12.|[2]Reozalimab. IMGT/mAb-DB.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15228454 1 Vial
Lentiviral mouse Cib3 shRNA (UAS) - Lentiviral mouse Cib3 shRNA (UAS, GFP) plasmid
Ask
View Details 
MBS600652-01 0.05 mg
DDX5 (DEAD (Asp-Glu-Ala-Asp) Box 5, DKFZp686J01190, G17P1, HLR1, HUMP68, p68)
Ask
View Details MBS600652-02 5x 0.05 mg
DDX5 (DEAD (Asp-Glu-Ala-Asp) Box 5, DKFZp686J01190, G17P1, HLR1, HUMP68, p68)
Ask
View Details